|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2005-8-3
|
|
pubmed:abstractText |
Response to neoadjuvant chemotherapy is used as an intermediate endpoint for breast cancer relapse and survival. Most breast cancer response classification systems use pathologic complete response, either alone or in conjunction with clinical assessments, to categorize response. We examined the ability of the revised 2003 American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system, which considers both the number of involved axillary lymph nodes and the extent of tumor in the breast to predict patient survival after neoadjuvant chemotherapy for breast cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:CareyLisa ALA,
pubmed-author:CollichioFrancesF,
pubmed-author:DeesE ClaireEC,
pubmed-author:GrahamMark LML,
pubmed-author:HalleJanJ,
pubmed-author:Klauber-DeMoreNancyN,
pubmed-author:MetzgerRichardR,
pubmed-author:MooreDominic TDT,
pubmed-author:OllilaDavid WDW,
pubmed-author:SartorCarolyn ICI,
pubmed-author:SawyerLyndaL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
97
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1137-42
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16077072-Adult,
pubmed-meshheading:16077072-Aged,
pubmed-meshheading:16077072-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16077072-Breast Neoplasms,
pubmed-meshheading:16077072-Chemotherapy, Adjuvant,
pubmed-meshheading:16077072-Disease-Free Survival,
pubmed-meshheading:16077072-Female,
pubmed-meshheading:16077072-Humans,
pubmed-meshheading:16077072-Lymph Node Excision,
pubmed-meshheading:16077072-Lymph Nodes,
pubmed-meshheading:16077072-Lymphatic Metastasis,
pubmed-meshheading:16077072-Mastectomy,
pubmed-meshheading:16077072-Middle Aged,
pubmed-meshheading:16077072-Neoadjuvant Therapy,
pubmed-meshheading:16077072-Neoplasm, Residual,
pubmed-meshheading:16077072-Neoplasm Staging,
pubmed-meshheading:16077072-Prognosis,
pubmed-meshheading:16077072-Proportional Hazards Models,
pubmed-meshheading:16077072-Survival Analysis,
pubmed-meshheading:16077072-United States
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
|
|
pubmed:affiliation |
Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599-7305, USA. Lisa_Carey@med.unc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
